-
Drug Discovery & Therapeutics2 days agoAntibody–drug conjugates amplify cancer immunotherapy in selected solid tumors
A review of clinical and preclinical evidence finds that antibody–drug conjugates can improve outcomes with immune checkpoint inhibitors in several solid tumors, but benefits depend heavily...
-
Drug Discovery & Therapeutics2 days agoReview maps lipid metabolic links to oxaliplatin resistance in colorectal cancer
A review of preclinical evidence finds that lipid-storage, fatty-acid oxidation, phospholipid and antioxidant programs can influence multiple processes linked to oxaliplatin resistance in colorectal cancer, but...
-
Drug Discovery & Therapeutics3 days agoNovel protein and peptide therapeutics
Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.
-
Drug Discovery & Therapeutics3 days agoBridging the capacity gap in advanced therapies
Nature Reviews Drug Discovery, Published online: 26 October 2026; doi:10.1038/d41573-026-00159-6Academic centres are increasingly central to advanced therapy development, but expanding clinical use will require stronger infrastructure,...
-
Drug Discovery & Therapeutics3 days ago
IL-21 mimic synergizes with KRAS inhibitors
Nature Reviews Drug Discovery, Published online: 26 October 2026; doi:10.1038/d41573-026-00170-xIL-21 mimic synergizes with KRAS inhibitors
-
Drug Discovery & Therapeutics3 days ago
Antagonizing adenosine receptors alleviates cardiac fibrosis
Nature Reviews Drug Discovery, Published online: 26 October 2026; doi:10.1038/d41573-026-00168-5Antagonizing adenosine receptors alleviates cardiac fibrosis
-
Drug Discovery & Therapeutics3 days ago
Nanotherapy targets senescent cells
Nature Reviews Drug Discovery, Published online: 26 October 2026; doi:10.1038/d41573-026-00167-6Nanotherapy targets senescent cells
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
